Discover cutting-edge progress in epilepsy research through Novotech CRO's in-depth disease analysis. Gain insights into novel therapeutic approaches, clinical trials, and future innovations shaping the future of epilepsy care.
Epilepsy is a chronic neurological condition marked by recurring seizures, which are involuntary movements affecting part or the entire body. Idiopathic generalized epilepsy is the most common form of epilepsy, accounting for one-fourth of all cases. Although the cause remains unknown in 50% of epilepsy cases, structural abnormalities, genetics, viral infections, metabolic disorders, and immunological factors play a key role. With appropriate antiepileptic drugs, up to 70% of individuals with epilepsy can become seizure-free.
Moving on to prevalence, epilepsy poses a significant burden worldwide, affecting approximately 46 million people globally. Asia-Pacific region recorded the highest prevalence, followed by North America, Europe, and the rest of the world regions. The country-wise prevalence showed variations, with India, China, the United States, Brazil, Mexico, Nigeria, and Germany having the highest number of cases among others.
With respect to the epilepsy treatment landscape, antiepileptic drugs (anticonvulsants) are the primary drug choice to prevent seizures in people with epilepsy, with a success rate of over 60%. Monotherapy is recommended over polytherapy to reduce side effects and costs. However, many people with epilepsy also experience psychiatric and cognitive issues, requiring comprehensive management. The increase in drug-resistant epilepsy cases has triggered the need for innovative treatments. Ongoing research efforts offer promising opportunities through the development of precision medicine, genetic therapies, and neurostimulation devices targeting specific epilepsy subtypes.
Regarding clinical trials, since 2019, the biotech and biopharma industry initiated over 4,000 epilepsy trials. Asia-Pacific leads in the number of trials conducted, followed by Europe, North America, and the rest of the world. Mainland China leads in the Asia Pacific, while Germany is prominent in Europe. The United States plays a major role in epilepsy trials in North America. Israel contributes moderately to the rest of the world's trials. With respect to patient recruitment trends, Asia-Pacific showed shorter recruitment durations and faster patient recruitment rates in comparison to the United States and Europe.
Next, moving on to marketed and pipeline drugs, there are various marketed drugs from companies like Advicenne S.A., and Pfizer Inc., along with other promising options in late-stage development. Likozam and Fycompa, which target the AMPA glutamate receptor, are already approved and marketed for the treatment of epilepsy. Additionally, the Phase III pipeline includes promising drugs such as Ztalmy and Ganaxolone. These target the GABA A receptor, suggesting advancements in epilepsy treatment options and focusing on exploring novel mechanisms of action to address the challenges of this disease.
In conclusion, epilepsy remains a global health concern, yet research and treatment are rapidly evolving, driven by an increased understanding of the complexity of this disease. Ongoing research presents promising opportunities to enhance epilepsy management through the advancement of non-pharmacological interventions and innovative therapies. Collaboration among researchers, healthcare providers, and pharmaceutical companies holds promise for further progress in epilepsy care.
Novotech, a global clinical Contract Research Organization (CRO), collaborates with biotech firms to accelerate advanced therapeutics development across all phases. Novotech has experience with over 5,000 clinical projects, offering a wide range of services including laboratories, Phase I facilities, and regulatory expertise. With 34 office locations and a team of 3,000+ professionals, Novotech is a trusted strategic partner for end-to-end solutions.
Discover more about epilepsy research by downloading our comprehensive disease report.